Supplementary Figure S3 from Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency
Antoine Simoneau(Io Therapeutics (United States)), Scott Throner(Tango Therapeutics (United States)), Wenhai Zhang(Tango Therapeutics (United States)), William D. Mallender(Millennium Engineering and Integration (United States)), Hsin‐Jung Wu(Tango Therapeutics (United States)), Yingnan Chen(Guangzhou Medical University), John P. Maxwell(Tango Therapeutics (United States)), Tenzing Khendu(Tango Therapeutics (United States)), Jannik N. Andersen(Tango Therapeutics (United States)), Douglas A. Whittington(Amgen (United States)), Yi Yu(Novartis (United States)), Sirimas Sudsakorn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shangtao Liu(Tango Therapeutics (United States)), Ashley H. Choi(Tango Therapeutics (United States)), Binzhang Shen(Tango Therapeutics (United States)), Samuel R. Meier, Hannah Stowe(Massachusetts General Hospital), Shreya S. Rajeswaran(Tango Therapeutics (United States)), Charlotte B. Pratt(Tango Therapeutics (United States)), Charlotte Grace Comer(Tango Therapeutics (United States)), Tianshu Feng(Tango Therapeutics (United States))
Cited by 0
Related Papers
A Quantitative Proteome Map of the Human Body
|Cell|2020|485
Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
|Molecular Cell|2010|461